Attovia Therapeutics Prices Upsized $289M IPO at Top of Range

Attovia Therapeutics priced its upsized initial public offering at $17.00 per share late Monday, raising $289 million after increasing the deal size by 45% from the original $200 million target. The San Carlos, California-based biotech offered 17 million shares, up from the 12.5 million originally filed, implying a fully diluted valuation of approximately $731.5 million. Shares are expected to begin trading on the Nasdaq Global Market under the ticker ATTO on Tuesday.

The upsizing signals strong institutional demand for immunology-focused biotech listings at a time when the IPO window has opened to earlier-stage companies. Pricing at the top of the $15 to $17 range with a 45% deal-size increase, Attovia is the first of three biotech IPOs expected this week; Braveheart Bio and Vogenx are scheduled to follow on August 6.

An IL-31 play in a Dupixent-dominated market

Attovia’s lead asset, ATTO-1310, is a half-life-extended fusion protein that inhibits interleukin-31, a cytokine central to itch signaling. The drug has completed dosing in a Phase 1 trial of 56 healthy volunteers, and preliminary Phase 1b data in patients with high-itch atopic dermatitis and chronic pruritus showed that 65% of patients met the company’s itch responder definition at Week 4 across two pooled dose cohorts. Phase 2 trials in chronic pruritus and high-itch atopic dermatitis are planned for the first half of 2027.

ATTO-1310 targets the IL-31 ligand directly, distinguishing it from Galderma’s Nemluvio (nemolizumab), which blocks the IL-31 receptor alpha subunit. Attovia argues the difference in target allows higher dosing and deeper itch relief through stronger pathway blockade. Nemluvio generated blockbuster revenue in 2025, and Galderma doubled its peak sales forecast to more than $4 billion this year, validating the commercial potential of IL-31 blockade.

The company’s ATTOBODY platform, in-licensed from Alamar Biosciences (which went public in April 2026), has produced two additional candidates still in preclinical development. ATTO-2306, a bispecific targeting IL-13 and IL-31, is in IND-enabling studies with a Phase 1 start planned for the first half of 2027. ATTO-1091, a trispecific targeting TL1A, IL-23, and integrin α4β7 for inflammatory bowel disease, is also in IND-enabling studies.

Financial position

Attovia had raised $255.8 million across Series A, B, and C rounds backed by Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives, and venBio. As of March 31, 2026, the company held $126.8 million in working capital. It posted a net loss of $64.1 million on $1.4 million in collaboration revenue for the 12 months ended March 31, 2026.

Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital are the joint bookrunners. Goldman Sachs Alternatives, not acting as an underwriter, holds a 5.7% stake through an affiliated entity.

What to watch

The IPO proceeds, combined with existing cash, extend Attovia’s runway to fund Phase 2 trials for ATTO-1310 and IND-enabling work for the bispecific and trispecific programs. The key question for investors is whether direct IL-31 ligand targeting can produce clinically meaningful differentiation against entrenched competitors, particularly Nemluvio and the broader IL-4/IL-13 class led by Dupixent. Phase 2 data in 2027 will provide the first real test.

What It Means for the Trade

An upsized deal pricing at the top of its range is institutional demand talking, and the message is that the market is paying for validated-mechanism immunology with early clinical signal — not for platform novelty alone. The $731.5 million fully diluted valuation on a company with Phase 1b data and a net loss of $64.1 million over twelve months is a bet on one number: whether ATTO-1310’s direct IL-31 ligand blockade produces meaningfully deeper itch control than the receptor-antibody approach Galderma’s Nemluvio already monetized. Nemluvio’s blockbuster trajectory and the doubled $4 billion-plus peak sales forecast did the market-education work for Attovia — investors can model the prize without trusting a new biology story. That cuts both ways: the validation is real, and so is the incumbent.

The standard IPO mechanics apply. The 45% upsizing and top-of-range print mean the deal was heavily oversubscribed — the after-market trading will tell you whether the flippers got absorbed, but the structural point is that Attovia enters public life with a syndicate of crossover-quality holders (Deep Track, Frazier, venBio, Goldman-affiliated stakes) whose entry prices sit well below $17. Lockup expiry, typically ~180 days out, lands before the Phase 2 data in H1 2027 — the classic sequencing problem where supply overhang arrives before the value-inflection catalyst. The disciplined way to own this is to underwrite the Phase 2 readout and let the lockup window do its discounting first.

Mechanism and Pipeline Context

The ligand-versus-receptor distinction is the whole investment claim, so it deserves a skeptical look. ATTO-1310 neutralizes IL-31 itself; Nemluvio blocks the IL-31 receptor alpha subunit. The theoretical argument for ligand targeting is stoichiometric: a soluble ligand sink can be dosed high enough to mop up pathway signaling more completely than receptor occupancy allows, and the half-life-extended fusion protein format is what makes sustained high exposure practical. The 65% itch-responder fraction at Week 4 across pooled Phase 1b dose cohorts is a preliminary signal, not a comparative claim — no head-to-head with nemolizumab exists, and cross-trial responder comparisons in itch trials are notoriously unreliable due to differing instruments, populations, and placebo arms. Phase 2 in chronic pruritus and high-itch atopic dermatitis, planned for H1 2027, is where dose-ranging either produces a clean pharmacodynamic story or it doesn’t.

The pipeline behind the lead is where the platform value sits: ATTO-2306 (IL-13 x IL-31 bispecific) and ATTO-1091 (TL1A x IL-23 x α4β7 trispecific for IBD) are both in IND-enabling studies. A trispecific against IBD is a genuinely ambitious construct — TL1A and IL-23 are both validated IBD targets, and integrin α4β7 blockade has an approved precedent — but the execution risk on multi-specific manufacturing and clinical development is the highest in the industry. Treat those as long-dated options funded by the IPO, not as near-term valuation support.

Risks and What Could Go Wrong

1. Phase 2 in 2027 fails to separate from placebo convincingly — itch endpoints have large placebo responses, and the dermatology trial design matters as much as the drug.
2. Nemluvio consolidates the IL-31 market before Attovia reads out: Galderma has the launch, the label, the dermatology relationships, and is already guiding to $4 billion-plus — two years of entrenchment is a real moat.
3. Dupixent-class coverage economics: payers already reimburse IL-4/IL-13 blockade broadly; a second biologic price point in dermatology faces step-therapy pressure from day one.
4. Half-life extension and immunogenicity: fusion-protein formats can work beautifully or trigger anti-drug antibodies; chronic dermatology use is unforgiving on both.

Position read: this is a post-IPO story priced at just under three times its last private round’s implied trajectory, with one real catalyst (2027 Phase 2) and a lockup before it. Accumulate into weakness if the thesis is intact; do not chase the debut.

---

Source: Reuters, Renaissance Capital, IPOScoop, FierceBiotech